In silico quest of selective naphthyl-based CREBBP bromodomain inhibitor
Tóm tắt
The reader proteins like bromodomains have recently gained increased attentions in the area of epigenetic drug discovery, as they are the potent regulators in gene transcription process. Among the other bromodomains, cAMP response element-binding protein (CREB) binding protein or CREBBP bomodomain involved in various cancer progressions and therefore, efforts to develop specific inhibitors of CREBBP bomodomain are of clinical value. In this study, we tried to identify selective CREBBP bromodomain inhibitor, which was accomplished by using molecular docking, free energy calculation and molecular dynamics (MD) simulation studies, considering a series of naphthyl based compounds. The docking procedure was validated by comparing root mean square deviations (RMSDs) of crystallographic complex to docked complex. Favorable electrostatic interactions with the Arg1173 side chain were considered to attain selectivity for CREBBP bromodomain over other human bromodomain subfamilies. We found that naphthyl-based compounds have greater binding affinities towards the CREBBP bromodomain, and formed non-bonded interactions with various side chain residues that are important for bromodomain inhibition. From detailed investigation by induced fit docking, compound 31 was found to have favorable electrostatic interactions with the Arg1173 side chain by forming conventional hydrogen bonds. This result was further confirmed by analyzing hydrogen bond occupancy and bonding distance during the molecular dynamics simulation. We believe that these findings offer useful insight for the designing of target specific new bromodomain inhibitor and also promote further structure guided synthesis of analogues for identification of potent CREBBP bromodomain inhibitors as well as detailed in vitro and in vivo analyses.
Tài liệu tham khảo
Aparna V, Dineshkumar K, Mohanalakshmi N, Velmurugan D, Hopper W (2014) Identification of natural compound inhibitors for multidrug efflux pumps of Escherichia coli and Pseudomonas aeruginosa using in silico high-throughput virtual screening and in vitro validation. PLoS One 9:e101840
Berman HM et al (2000) The protein data bank. Nucleic Acids Res 28:235–242
Conery AR et al (2016) Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. Elife 5:e10483
Das C, Lucia MS, Hansen KC, Tyler JK (2009) CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 459:113–117
Dash R et al (2015) In silico analysis of indole-3-carbinol and its metabolite DIM as EGFR tyrosine kinase inhibitors in platinum resistant ovarian cancer vis a vis ADME/T property analysis. J App Pharm Sci 5(11):073–078
Doman TN et al (2002) Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem 45:2213–2221
Filippakopoulos P, Knapp S (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13:337–356
Florence B, Faller DV (2001) You bet-cha: a novel family of transcriptional regulators. Front Biosci 6:D1008–D1018
Friesner RA et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749
Friesner RA et al (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes. J Med Chem 49:6177–6196
Giles RH, Peters DJ, Breuning MH (1998) Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14:178–183
Goodman RH, Smolik S (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev 14:1553–1577
Hammitzsch A et al (2015) CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci 112:10768–10773
Harmange J-C et al (2008) Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation. J Med Chem 51:1649–1667
Hay DA et al (2014) Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc 136:9308–9319
Hewings DS et al (2011) 3, 5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem 54:6761–6770
Hou T, Wang J, Li Y, Wang W (2010) Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model 51:69–82
Hu X, Hong L, Smith MD, Neusius T, Cheng X, Smith JC (2015) The dynamics of single protein molecules is non-equilibrium and self-similar over thirteen decades in time. Nat Phys 12:171–174
Ito A, Lai CH, Zhao X, Si Saito, Hamilton MH, Appella E, Yao TP (2001) p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20:1331–1340
Jacobson RH, Ladurner AG, King DS, Tjian R (2000) Structure and function of a human TAFII250 double bromodomain module. Science 288:1422–1425
Jatana N, Sharma A, Latha N (2013) Pharmacophore modeling and virtual screening studies to design potential COMT inhibitors as new leads. J Mol Gr Model 39:145–164
Jin Q et al (2011) Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J 30:249–262
Kuhn B, Gerber P, Schulz-Gasch T, Stahl M (2005) Validation and use of the MM-PBSA approach for drug discovery. J Med Chem 48:4040–4048
Labute P (2008) The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem 29:1693–1698
Li M et al (2011a) High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J Transl Med 9:1
Li Y, Yang H-X, Luo R-Z, Zhang Y, Li M, Wang X, Jia W-H (2011b) High expression of p300 has an unfavorable impact on survival in resectable esophageal squamous cell carcinoma. Ann Thorac Surg 91:1531–1538
Mujtaba S et al (2004) Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell 13:251–263
Müller S, Knapp S (2014) Discovery of BET bromodomain inhibitors and their role in target validation. MedChemComm 5:288–296
Muller S, Filippakopoulos P, Knapp S (2011) Bromodomains as therapeutic targets. Expert Rev Mol Med 13:e29
Phillips JC et al (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26:1781–1802. https://doi.org/10.1002/jcc.20289
Picaud S et al (2015) Generation of a selective small molecule inhibitor of the CBP/p300 bromodomain for leukemia therapy. Can Res 75:5106–5119
Poplawski A et al (2014) Molecular insights into the recognition of N-terminal histone modifications by the BRPF1 bromodomain. J Mol Biol 426:1661–1676. https://doi.org/10.1016/j.jmb.2013.12.007
Priya Doss CG, Chakraborty C, Chen L, Zhu H (2014) Integrating in silico prediction methods, molecular docking, and molecular dynamics simulation to predict the impact of ALK missense mutations in structural perspective. BioMed Res Int 2014:895831
Rastelli G, Rio AD, Degliesposti G, Sgobba M (2010) Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA. J Comput Chem 31:797–810
Romero FA, Taylor AM, Crawford TD, Tsui V, Côté A, Magnuson S (2015) Disrupting acetyl-lysine recognition: progress in the development of bromodomain inhibitors. J Med Chem 59:1271–1298
Rooney TP et al (2014) A series of potent CREBBP bromodomain ligands reveals an induced-fit pocket stabilized by a cation–π interaction. Angew Chem Int Ed 53:6126–6130
Schrödinger S (2012) Induced fit docking protocol; glide version 5.8, prime version 3.1. Schrödinger LLC, New York
Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403:41–45
Talele TT, McLaughlin ML (2008) Molecular docking/dynamics studies of Aurora A kinase inhibitors. J Mol Gr Model 26:1213–1222
Tanwar H, Sneha P, Kumar DT, Siva R, Walter CEJ, Doss CGP (2017) Chapter five-A computational approach to identify the biophysical and structural aspects of methylenetetrahydrofolate reductase (MTHFR) mutations (A222V, E429A, and R594Q) leading to schizophrenia. Adv Protein Chem Struct Biol 108:105–125
Taylor AM et al (2016) Fragment-based discovery of a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor (CPI-637). ACS Med Chem Lett 7(5):531–536
Unzue A, Xu M, Dong J, Wiedmer L, Spiliotopoulos D, Caflisch A, Nevado C (2015) Fragment-based design of selective nanomolar ligands of the CREBBP bromodomain. J Med Chem 59:1350–1356
Unzue A et al (2016) The “Gatekeeper” residue influences the mode of binding of acetyl indoles to bromodomains. J Med Chem 59:3087–3097
Vanommeslaeghe K et al (2010) CHARMM general force field (CGenFF): a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem 31:671–690. https://doi.org/10.1002/jcc.21367
Vidler LR, Brown N, Knapp S, Hoelder S (2012) Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem 55:7346–7359
Weis A, Katebzadeh K, Söderhjelm P, Nilsson I, Ryde U (2006) Ligand affinities predicted with the MM/PBSA method: dependence on the simulation method and the force field. J Med Chem 49:6596–6606
Wichapong K, Rohe A, Platzer C, Slynko I, Erdmann F, Schmidt M, Sippl W (2014) Application of docking and QM/MM-GBSA rescoring to screen for novel Myt1 kinase inhibitors. J Chem Inf Model 54:881–893
Xu M, Unzue A, Dong J, Spiliotopoulos D, Nevado C, Caflisch A (2015) Discovery of CREBBP bromodomain inhibitors by high-throughput docking and hit optimization guided by molecular dynamics. J Med Chem 59:1340–1349